A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

NCT02503189 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-05-17

No results posted yet for this study

Summary

The purpose of this study is to investigate the superiority of KCT-0809 to placebo, and to evaluate safety in dry eye patients with Sjögren's syndrome

Conditions

  • Dry Eye With Sjögren's Syndrome

Interventions

DRUG

KCT-0809 ophthalmic solution

DRUG

Placebo

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2017-01-31

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02503189 on ClinicalTrials.gov